the discontinuation data on GLP-1s is the part nobody talks about
Everyone quotes the efficacy numbers. Almost nobody quotes what happens after stopping.
The published withdrawal and extension data across this class shows substantial regain after discontinuation. A large fraction of what was lost, over about a year.
This isn't a knock on the drugs. It's arguably what you'd expect if the mechanism addresses an ongoing regulatory process rather than producing a permanent change. Stop a blood pressure med and blood pressure comes back too, nobody calls that a failure of the drug.
But it does reframe what these are. They look like ongoing management rather than a course of treatment, and that has consequences for cost, adherence, supply and how people plan.
This is human data from randomized withdrawal and extension phases of registered trials, so reasonably strong.
I think it gets skipped because it makes the story less exciting. Which is exactly why it's worth saying.